Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1

This article was originally published here

The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-clinical components to the

The post Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply